Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
41.07
-0.80 (-1.91%)
At close: Dec 10, 2025, 4:00 PM EST
41.38
+0.31 (0.75%)
After-hours: Dec 10, 2025, 7:29 PM EST
Exelixis Revenue
Exelixis had revenue of $597.76M in the quarter ending September 30, 2025, with 10.79% growth. This brings the company's revenue in the last twelve months to $2.09B, up 21.35% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.09B
Revenue Growth
+21.35%
P/S Ratio
4.96
Revenue / Employee
$1,994,959
Employees
1,147
Market Cap
11.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EXEL News
- 7 days ago - Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
- 9 days ago - 2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
- 4 weeks ago - Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 4 weeks ago - Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still - Seeking Alpha
- 4 weeks ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November - Business Wire
- 5 weeks ago - Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 7 weeks ago - Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire